From CAR-Ts to T cell engagers: Translating early learnings beyond oncology
02 Sept 2026
Bi/Multispecifics
- What has CAR-T already taught us about the biology of durable responses in autoimmune diseases beyond oncology?
- Can T cell engagers reproduce the key benefits of CAR-T while improving control, access, and scalability.
- Which diseases and target-cell populations are best suited for a T cell engager approach.
- What safety profile is required for broader use in chronic disease?
- What translational evidence is needed to identify viable T cell engager program for non oncology indications?
- Closing question: What is the single most important lesson from CAR-T that should influence the design of the next generation of T cell engagers for autoimmune and chronic diseases.
